239 related articles for article (PubMed ID: 14707062)
1. Invariant chain and the MHC class II cytoplasmic domains regulate localization of MHC class II molecules to lipid rafts in tumor cell-based vaccines.
Dolan BP; Phelan TP; Ilkovitch D; Qi L; Wade WF; Laufer TM; Ostrand-Rosenberg S
J Immunol; 2004 Jan; 172(2):907-14. PubMed ID: 14707062
[TBL] [Abstract][Full Text] [Related]
2. Presentation of endogenously synthesized MHC class II-restricted epitopes by MHC class II cancer vaccines is independent of transporter associated with Ag processing and the proteasome.
Dissanayake SK; Tuera N; Ostrand-Rosenberg S
J Immunol; 2005 Feb; 174(4):1811-9. PubMed ID: 15699107
[TBL] [Abstract][Full Text] [Related]
3. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
Dolan BP; Gibbs KD; Ostrand-Rosenberg S
J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
[TBL] [Abstract][Full Text] [Related]
4. Single amino acid mutations in the murine MHC class II A beta cytoplasmic domain abrogate antigen presentation.
Laufer TM; Smiley ST; Ranger A; Clements VK; Ostrand-Rosenberg S; Glimcher LH
J Immunol; 1997 Dec; 159(12):5914-20. PubMed ID: 9550388
[TBL] [Abstract][Full Text] [Related]
5. Intracytoplasmic domains of MHC class II molecules are essential for lipid-raft-dependent signaling.
Bécart S; Setterblad N; Ostrand-Rosenberg S; Ono SJ; Charron D; Mooney N
J Cell Sci; 2003 Jun; 116(Pt 12):2565-75. PubMed ID: 12766188
[TBL] [Abstract][Full Text] [Related]
6. MHC class II molecules traffic into lipid rafts during intracellular transport.
Poloso NJ; Muntasell A; Roche PA
J Immunol; 2004 Oct; 173(7):4539-46. PubMed ID: 15383586
[TBL] [Abstract][Full Text] [Related]
7. Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo.
Qi L; Rojas JM; Ostrand-Rosenberg S
J Immunol; 2000 Nov; 165(10):5451-61. PubMed ID: 11067897
[TBL] [Abstract][Full Text] [Related]
8. Effect of decreasing the affinity of the class II-associated invariant chain peptide on the MHC class II peptide repertoire in the presence or absence of H-2M.
Honey K; Forbush K; Jensen PE; Rudensky AY
J Immunol; 2004 Apr; 172(7):4142-50. PubMed ID: 15034026
[TBL] [Abstract][Full Text] [Related]
9. MHC class II-peptide complexes and APC lipid rafts accumulate at the immunological synapse.
Hiltbold EM; Poloso NJ; Roche PA
J Immunol; 2003 Feb; 170(3):1329-38. PubMed ID: 12538693
[TBL] [Abstract][Full Text] [Related]
10. Invariant chain alters the malignant phenotype of MHC class II+ tumor cells.
Clements VK; Baskar S; Armstrong TD; Ostrand-Rosenberg S
J Immunol; 1992 Oct; 149(7):2391-6. PubMed ID: 1527384
[TBL] [Abstract][Full Text] [Related]
11. Lipid rafts, major histocompatibility complex molecules, and immune regulation.
Goebel J; Forrest K; Flynn D; Rao R; Roszman TL
Hum Immunol; 2002 Oct; 63(10):813-20. PubMed ID: 12368033
[TBL] [Abstract][Full Text] [Related]
12. Modulation of antigen presentation and class II expression by a class II-associated invariant chain peptide.
Zechel MA; Chaturvedi P; Lee-Chan EC; Rider BJ; Singh B
J Immunol; 1996 Jun; 156(11):4232-9. PubMed ID: 8666792
[TBL] [Abstract][Full Text] [Related]
13. A model for antigen-specific T-cell anergy: displacement of CD4-p56(lck) signalosome from the lipid rafts by a soluble, dimeric peptide-MHC class II chimera.
Thomas S; Kumar R; Preda-Pais A; Casares S; Brumeanu TD
J Immunol; 2003 Jun; 170(12):5981-92. PubMed ID: 12794125
[TBL] [Abstract][Full Text] [Related]
14. Cathepsin S controls MHC class II-mediated antigen presentation by epithelial cells in vivo.
Beers C; Burich A; Kleijmeer MJ; Griffith JM; Wong P; Rudensky AY
J Immunol; 2005 Feb; 174(3):1205-12. PubMed ID: 15661874
[TBL] [Abstract][Full Text] [Related]
15. Concentration of MHC class II molecules in lipid rafts facilitates antigen presentation.
Anderson HA; Hiltbold EM; Roche PA
Nat Immunol; 2000 Aug; 1(2):156-62. PubMed ID: 11248809
[TBL] [Abstract][Full Text] [Related]
16. MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.
Ilkovitch D; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2004 Jun; 53(6):525-32. PubMed ID: 14730400
[TBL] [Abstract][Full Text] [Related]
17. Distinct MHC class II molecules are associated on the dendritic cell surface in cholesterol-dependent membrane microdomains.
Khandelwal S; Roche PA
J Biol Chem; 2010 Nov; 285(46):35303-10. PubMed ID: 20833718
[TBL] [Abstract][Full Text] [Related]
18. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide.
van Bergen J; Camps M; Offringa R; Melief CJ; Ossendorp F; Koning F
Cancer Res; 2000 Nov; 60(22):6427-33. PubMed ID: 11103809
[TBL] [Abstract][Full Text] [Related]
19. Polarized transport of MHC class II molecules in Madin-Darby canine kidney cells is directed by a leucine-based signal in the cytoplasmic tail of the beta-chain.
Simonsen A; Pedersen KW; Nordeng TW; von der Lippe A; Stang E; Long EO; Bakke O
J Immunol; 1999 Sep; 163(5):2540-8. PubMed ID: 10452991
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy by antisense suppression of Ii protein in MHC-class-II-positive tumor cells.
Qiu G; Goodchild J; Humphreys RE; Xu M
Cancer Immunol Immunother; 1999 Dec; 48(9):499-506. PubMed ID: 10602887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
